A Study to Test the Safety of Three Experimental HIV Vaccines
Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001
Trial Information
Current as of January 15, 2025
Completed
Keywords
ClinConnect Summary
There are currently several Phase I and II clinical trials being performed within AVEG to evaluate different HIV-1 vaccine candidates. The HIV-1 vaccination approach that is furthest along the clinical development pathway is the so-called prime-boost regimen of live recombinant canarypox priming (ALVAC-HIV vCP205) with recombinant subunit protein boosting (HIV-1 SF-2 rgp120 in MF59 adjuvant). The protein boost enhances neutralizing antibody responses against laboratory strains of HIV-1 in assays performed in vitro, as well as enhancing CD4 cell response and increasing the frequency of CD8 c...
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- You may be eligible for this study if you:
- • Are between the ages of 18 and 60.
- • Are HIV-negative.
- • Are negative for Hepatitis B.
- • Have a normal physical exam.
- • Are available for 18 months of follow-up.
- • Agree to use an effective method of birth control for 1 month before receiving a vaccine and during the study.
- • Exclusion Criteria
- You will not be eligible for this study if you:
- • Have a history of an immunodeficiency, chronic illness, or cancer.
- • Have a medical or psychiatric condition which would make you unable to comply with the study.
- • Are at higher-risk for HIV infection; for example, have a history of injection drug use in the past year or practice higher risk sexual behavior.
- • Have syphilis or tuberculosis.
- • Have received a live vaccine in the past 60 days, have ever received an HIV vaccine or placebo in a previous HIV vaccine study, or have ever received a rabies vaccine.
- • Have a history of a serious allergic reaction to a vaccine or to any other substance, including neomycin or egg products.
- • Have received certain medications.
- • Are pregnant or breast-feeding.
Trial Officials
Mark J Mulligan, MD
Study Chair
Univ of Alabama at Birmingham
About National Institute Of Allergy And Infectious Diseases (Niaid)
The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nashville, Tennessee, United States
Seattle, Washington, United States
Rochester, New York, United States
Saint Louis, Missouri, United States
Baltimore, Maryland, United States
Birmingham, Alabama, United States
Seattle, Washington, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials